Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 8/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8549355 | 0.81 | F2 (0.52) | STSF2 | |
| SCHEMBL10194489 | 0.81 | ACACB (0.71) | ACACBTGFBR1 | |
| SCHEMBL6787195 | 0.81 | CTSS (0.56) | ACACBCTSSF2PKMTPSAB1 | |
| SCHEMBL6786683 | 0.81 | ACACB (0.64) | ACACBCTSSF2PKMTPSAB1 | |
| Hydrochloric Acid SCHEMBL6786751 | 0.80 | CTSS (0.55) | ACACBCTSSF2PKMTPSAB1 | |
| SCHEMBL6793490 | 0.80 | F10 (0.61) | CTSSF2PKMTPSAB1 | |
| SCHEMBL10194548 | 0.78 | SFRP1 (0.56) | ACACBSTSTGFBR1 | |
| SCHEMBL6792475 | 0.77 | PKM (0.47) | CTSSF2PKMTPSAB1 | |
| SCHEMBL6792902 | 0.77 | PKM (0.52) | CTSSF2PKMTPSAB1 | |
| SCHEMBL10194504 | 0.76 | ACACB (0.59) | ACACBTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| CN-1164232-A | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LTD (GB) | 1997-11-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | ACACB 4066/4885STS 145/4885CTSS 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.